Egide (ALGID) H1 2025 earnings summary

Executive summary

• Consolidated revenue for H1 2025 reached €15.58M, up 1% year-over-year, driven by strong recovery in Egide SA (+11%) and Egide USA (+10%), offsetting a 35% drop at Santier.

• EBITDA turned positive at €182K, a €559K improvement from H1 2024, reflecting operational efficiency and cost control.

• Net loss widened to -€2.04M from -€1.45M year-over-year, mainly due to higher depreciation, provisions, financial charges, and Santier’s decline.

Financial highlights

• Revenue: €15.58M (+1% year-over-year).

• EBITDA: €182K (vs. -€377K in H1 2024).

• Net loss: -€2.04M (vs. -€1.45M in H1 2024).

• Shareholders’ equity: €4.25M as of June 30, 2025 (19.8% of total assets).

• Net debt reduced to €5.70M from €7.51M at year-end 2024.

Outlook and guidance

• Revenue growth and EBITDA improvement expected in H2 2025, led by Egide SA and Egide USA.

• Santier’s activity expected to remain weak, with active search for new programs.

• Focus on operational profitability, client diversification, and expanding the customer base in defense and aerospace.